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Although a peptide vaccination is potentially useful for
cancers, there are some patients who do not show clini-
cally beneficial response to this treatment. Previously,
we have demonstrated gene expression profiling of pre-
vaccination peripheral blood mononuclear cells in
advanced castration-resistant prostate cancer patients
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with personalized peptide vaccination, and we have
found some genes related with overall survival. In this
study, we sequenced the upstream region of Haptoglo-
bin (HP), which is the most significant q-value in a uni-
variate Cox regression analysis (q-value=0.001) and
highly expressed in patients with poor clinical response.
Genetic polymorphism of the upstream of HP was iden-
tified and this polymorphism classifies patients with
good or poor clinical response to a peptide vaccination.
Our results suggested that mRNA level and genetic
polymorphism of HP is related to the prognosis of
advanced castration-resistant prostate cancer patients
treated with peptide vaccination.
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